Tenapanor hydrochloride

Tenapanor Hydrochloride is a pharmaceutical drug used primarily for the treatment of irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia. It is a first-in-class, small molecule, minimally systemic inhibitor of the sodium-hydrogen exchanger 3 (NHE3), an antiporter ion pump present on the apical surface of the gastrointestinal tract.

Mechanism of Action

Tenapanor Hydrochloride acts by inhibiting the NHE3 ion pump, which reduces the absorption of dietary sodium in the gut. This leads to an increase in the amount of water in the gut, which can help to soften stools and reduce constipation. In the case of hyperphosphatemia, the increased gut fluid and reduced sodium absorption can also help to reduce the absorption of dietary phosphate.

Clinical Use

Tenapanor Hydrochloride is used in the treatment of IBS-C and hyperphosphatemia. It has been shown to be effective in reducing the symptoms of IBS-C, including abdominal pain and bloating, and in improving stool consistency. In patients with hyperphosphatemia, it can help to reduce serum phosphate levels.

Side Effects

Common side effects of Tenapanor Hydrochloride include diarrhea, bloating, and abdominal pain. These side effects are usually mild and temporary. More serious side effects can include severe diarrhea and dehydration.

Development and Approval

Tenapanor Hydrochloride was developed by Ardelyx, a biopharmaceutical company based in California, USA. It was approved by the Food and Drug Administration (FDA) in 2019 for the treatment of IBS-C and in 2020 for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis.

See Also

• Irritable bowel syndrome
• Hyperphosphatemia
• Sodium-hydrogen exchanger 3
• Ardelyx
• Food and Drug Administration